Drive better outcomes and product success by transitioning your HCP and patient engagement to better address their specific needs along the diagnostic and treatment journey.
Delivering engagements that resonate with HCPs and patients in today’s complex healthcare landscape is a challenge. One must enhance the HCP experience with personalised content balanced between face-to-face and digital interactions. Patients who have faced a long and often arduous journey to diagnosis need emotional and clinical support.
Delivering these engagement strategies requires dedicated, personalized MSLs, reps, omnichannel engagement and patient support programmes – all playing an integral role in successfully engaging and supporting your customers.
But do you have the training, development, and team in place to deliver on the requirements of HCPs and patients today and in the future?
Inizio Engage commissioned an independent market research report looking to understand what the future of HCP and patient engagement will look like, engaging 22 global Pharma leaders situated in Europe from a total of 12 pharmaceutical companies.
We then shared these insights with workshop attendees at industry conferences and gained real-time feedback on the investment and progress of this transformation.
While you’ll be very familiar with the trends dominating conversations, we believe it’s critical to continue interrogating where organizations really are on the customer engagement transformation journey.
84% of pharma leaders surveyed identified investment in non-promotional, MSL-led scientific engagement is ‘critical’ or ‘very important’.
“MSLs need to be more business-minded and comfortable engaging digitally, working with HCP engagement data, and partnering with HCPs to improve patient outcomes.”
“Part of the MSL’s job is to be real partners with healthcare professionals. So let’s say, if you’re a doctor, I can come and basically tell you, today I want to help you improve the adherence of your patients. I’m going to help you implement some tools and initiatives to improve patient adherence and outcomes.”
“There should be no difference between commercial and medical in terms of omnichannel. It’s there for the customer. The channels themselves they might be, some of them might be closer to scientific and medical discussion and others might be closer to let’s say commercial product storytelling, but they all need to interplay.”
For more market research and survey data, download our report:
